Real-world treatment patterns among patients diagnosed with hormone receptor-positive metastatic breast cancer in the USA.

Zhu K, Omene CO, Stroup A, Bandera EV, Khosrow-Khavar F. Real-world treatment patterns among patients diagnosed with hormone receptor-positive metastatic breast cancer in the USA. Br J Clin Pharmacol. 2025;91:3401-3411.

2025

Real-world neoadjuvant and adjuvant trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021.

Zhao H, Shen C, Laureano JJ, et al. Real-world neoadjuvant and adjuvant trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021. Breast Cancer Res Treat. 2025;210(1):191-203.

2025

Challenges in HER2-low breast cancer identification, detection, and treatment.

Wu Q, Xu L. Challenges in HER2-low breast cancer identification, detection, and treatment. Transl Breast Cancer Res. 2024;5:3.

2024

Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists guideline update.

Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists guideline update. J Clin Oncol. 2023;41(22):3867-3872.

2023

Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients.

Wekking D, Porcu M, Pellegrino B, et al. Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients. ESMO Open. 2023;8(6):102043.

2023

Real-world treatment patterns and survival outcomes in metastatic triple negative breast cancer: immunotherapy- versus anti-angiogenic therapy-combined-with-chemotherapy.

Wang Y, Wu S, Li J, et al. Real-world treatment patterns and survival outcomes in metastatic triple negative breast cancer: immunotherapy- versus anti-angiogenic therapy-combined-with-chemotherapy. Cancer Med. 2025;14:e71164.

2025

Trastuzumab emtansine for residual invasive HER2-positive breast cancer.

von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617-628.

2019

Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer.

Viale G, Basik M, Niikura N, et al. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer. ESMO Open. 2023;8:101615.

2023

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791.

2012

Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trials.

Udovica S, Bartsch R, Singer CF, et al. Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trials. NPJ Breast Cancer. 2026;12:83.

2026

The global landscape of treatment standards for breast cancer.

Trapani D, Douillard JY, Winer EP, et al. The global landscape of treatment standards for breast cancer. J Natl Cancer Inst. 2021;113:1143-1155.

2021

Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United States.

Tolaney SM, Punie K, Carey LA, et al. Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United States. ESMO Open. 2024;9:103691.

2024

Real-world efficacy of immediate subsequent lines of therapy after trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (MBC)—retrospective study from the nationwide Flatiron database.

Tarantino P, Foldi J, et al. Real-world efficacy of immediate subsequent lines of therapy after trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (MBC)—retrospective study from the nationwide Flatiron database. Clin Cancer Res. 2025;31(12 suppl):P1-08-08.

2025

Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis—focus on proactive monitoring, diagnosis, and management.

Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis—focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022;106:102378.

2022

Micro-habits for life-long learning.

Shnayder-Adams MM, Sekhar A. Micro-habits for life-long learning. Abdom Radiol (NY). 2021;46:5509-5512.

2021

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.

Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423-1433.

2023

Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists.

Rugo HS, Bardia A, Gradishar WJ, et al. Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists. Breast. 2025;82:104485.

2025

Advances in research and current challenges in the treatment of advanced HER2-low breast cancer.

Qin Q. Advances in research and current challenges in the treatment of advanced HER2-low breast cancer. Front Cell Dev Biol. 2025;13:1451471.

2025

Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study.

Nozawa K, Iwata H, Mukohara T, et al. Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study. ESMO Open. 2025;10:105511.

2025

Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer.

Nezirevic S, Anders C, Dent S, et al. Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer. Breast Cancer Res Treat. 2025;214:329-337.

2025

Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer.

Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597-609.

2020

Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.

Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9-20.

2022

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Modi S, Jacot W, Iwata H, et al. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nat Med. 2025;31:4205-4213.

2025

Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States.

Modi S, Byng D, Zhang S, et al. Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States. Breast. 2026;86:104721.

2026

Real-world analysis of HER2-ultralow in HR+/HER2- metastatic breast cancer: prevalence and first-line chemotherapy outcomes.

Mathiot L, Kerdraon O, Le Borgne F, et al. Real-world analysis of HER2-ultralow in HR+/HER2- metastatic breast cancer: prevalence and first-line chemotherapy outcomes. Ther Adv Med Oncol. 2025;17:17588359251378863.

2025

Trastuzumab deruxtecan in residual HER2-positive early breast cancer.

Loibl S, Park YH, Shao Z, et al. Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N Engl J Med. 394(9):845-857.

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.

Loibl S, Loirat D, Tolaney SM, et al. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. Eur J Cancer. 2023;178:23-33.

2023

Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial.

Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38:2610-2619.

2020

New drugs, new toxicities: side effects of new and emerging breast cancer therapies.

LeVee A, Deutsh A, Lindgren ES, et al. New drugs, new toxicities: side effects of new and emerging breast cancer therapies. Am Soc Clin Oncol Educ Book. 2025;45:e473384.

2025

Toxicities and management strategies of emerging antibody-drug conjugates in breast cancer.

Kang S, Kim SB. Toxicities and management strategies of emerging antibody-drug conjugates in breast cancer. Ther Adv Med Oncol. 2025;17:17588359251324889.

2025

Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study.

Jourdain H, Di Meglio A, Mansouri I, Desplas D, Zureik M, Haddy N. Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study. ESMO Open. 2024;9:104083.

2024

Real-world treatment patterns and outcomes among patients with HER2-positive unresectable or metastatic breast cancer in China.

Huang J, Chen L, Song L, et al. Real-world treatment patterns and outcomes among patients with HER2-positive unresectable or metastatic breast cancer in China. Front Oncol. 2025;15:1527990.

2025

A critical theoretical approach to cancer disparities: breast cancer and the social determinants of health.

Gehlert S, Hudson D, Sacks T. A critical theoretical approach to cancer disparities: breast cancer and the social determinants of health. Front Public Health. 2021;9:674736.

2021

Retrospective observational study of outcomes in HER2-positive metastatic breast cancer (mBC) patients treated with ado-trastuzumab emtansine (T-DM1) and subsequent treatments after T-DM1 in the United States.

Denduluri N, Espirito JL, Hackshaw MD, Wentworth C, Recchia T, Kwong WJ. Retrospective observational study of outcomes in HER2-positive metastatic breast cancer (mBC) patients treated with ado-trastuzumab emtansine (T-DM1) and subsequent treatments after T-DM1 in the United States. Drugs Real World Outcomes. 2023;10:177-186.

2023

Sacituzumab govitecan in untreated, advanced triple-negative breast cancer.

Cortes J, Punie K, Barrios C, et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med. 2025;393:1912-1925.

2025

Safety profile of trastuzumab deruxtecan in advanced breast cancer: expert opinion on adverse event management.

Ciruelos E, Garcia-Saenz JA, Gavila J, Martin M, Rodriguez CA, Rodriguez-Lescure A. Safety profile of trastuzumab deruxtecan in advanced breast cancer: expert opinion on adverse event management. Clin Transl Oncol. 2024;26:1539-1548.

2024

Breast cancer treatments: updates and new challenges.

Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Pers Med. 2021;11:808.

2021

Barriers to treatment in patients with locally advanced breast cancer.

Bourdeanu L, Luu T, Baker N, et al. Barriers to treatment in patients with locally advanced breast cancer. J Natl Compr Canc Netw. 2013;11:1193-1198.

2013

Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: the DE-REAL study.

Botticelli A, Caputo R, Scagnoli S, et al. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: the DE-REAL study. Oncologist. 2024;29:303-310.

2024

Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression.

Bardia A, Rugo HS, Tolaney SM, et al. Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol. 2024;42:1738-1744.

2024

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01.

Bardia A, Jhaveri K, Im SA, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2025;43:285-296.

2025

Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer.

Bardia A, Hu X, Dent R, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391:2110-2122.

2024

Multidisciplinary breast cancer resources.

Association of Community Cancer Centers. Multidisciplinary breast cancer resources. ACCC website. Accessed September 5, 2026. Available at: https://www.accc-cancer.org/education-and-resources/cancer-types/breast-cancer/multidisciplinary-breast-cancer-resources

2026

Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases.

Anders C, Neuberger E, Schwartz NRM, et al. Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases. Int J Clin Oncol. 2025;30:1982-1991.

2025

Real-world clinical outcomes in patients with HER2+ metastatic breast cancer receiving tucatinib-based therapy after 2 or more prior metastatic HER2-directed regimens.

Anders C, Neuberger E, Bartley K, et al. Real-world clinical outcomes in patients with HER2+ metastatic breast cancer receiving tucatinib-based therapy after 2 or more prior metastatic HER2-directed regimens. Cancer Control. 2025;32:10732748251327711.

2025